Sharekhan

Piramal Pharma Ltd

Tue 18/11/2025,15:59:13 NSE: PPLPHARMA

₹ 192.13 -3.34 (-1.71%)
BUY NOW Buy Piramal Pharma Ltd Stock

Open Free Demat and Trading account in 15 minutes

Home Stock Piramal Pharma Ltd

Tue 18/11/2025,16:1:0

Piramal Pharma Ltd

Tue 18/11/2025,15:59:13 | NSE : PPLPHARMA

₹ 192.13-3.34 (-1.71%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 195.47

Previous Close

₹ 195.47

Volume

2356015

Mkt Cap ( Rs. Cr)

₹25538.84

High

₹ 195.88

Low

₹ 191.60

52 Week High

₹ 283.90

52 Week Low

₹ 181.73

Book Value Per Share

₹ 59.53

Dividend Yield

0.00

Face Value

₹ 10.00

What’s Your Call?

Collective community sentiment on Piramal Pharma Ltd

Your Vote -

Buy

64.37%

Hold

11.88%

Sell

23.75%

64.37%

261 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

192.13

617

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

617

Option Chain

Analyzes market sentiment, predicts Piramal Pharma Ltd' movement.

Call Price Open interest Strike Price Put Price Open interest

News

Media spotlight triggers stock stock attention, sentiment.

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    24 Oct 2025, 12:13PM Pursuant to Regulation 30(6) of the SEBI Listing Regulations, please find enclosed herewith the details of the Conference Call with investors/ analyst

  • Piramal Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    7 Nov 2025, 3:18PM Piramal Pharma Limited has informed the Exchange about Transcript

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    7 Nov 2025, 3:13PM Please see enclosed Transcript of Conference Call on the Unaudited Financial Results (Standalone & Consolidated) for the quarter ended September 30, 2

  • Piramal Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    6 Nov 2025, 12:31PM Piramal Pharma Limited has informed the Exchange about Link of Recording

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    6 Nov 2025, 12:26PM Audio Recording of Conference Call on the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th September, 2025

  • Piramal Pharma - Investor Presentation

    5 Nov 2025, 9:05PM Piramal Pharma Limited has informed the Exchange about Investor Presentation

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Investor Presentation

    5 Nov 2025, 9:05PM Please see enclosed Investor Presentation - Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and half year ended

  • Piramal Pharma - Press Release

    5 Nov 2025, 9:03PM Piramal Pharma Limited has informed the Exchange regarding a press release dated November 05, 2025, titled ""Piramal Pharma Limited Announces Results

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    5 Nov 2025, 9:03PM Please see enclosed Press Release - Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and half year ended Septemb

  • Piramal Pharma Q2 net profit down 6.54% at Rs 196.33 cr

    5 Nov 2025, 9:01PM The company reported standalone net profit of Rs 196.33 crore for the quarter ended September 30, 2025 as compared to Rs 210.06 crore in the same peri

  • Piramal Pharma - Results - Financial Results For Quarter Ended September 30, 2025

    5 Nov 2025, 9:00PM Please find enclosed Unaudited Financial Results (Standalone & Consolidated) for quarter ended September 30, 2025

  • Piramal Pharma - Outcome of Board Meeting

    5 Nov 2025, 8:55PM Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.

  • Piramal Pharma - Board Meeting Outcome for Outcome Of Board Meeting Dated November 5, 2025

    5 Nov 2025, 8:55PM Please find enclosed outcome of Board Meeting held on November 5, 2025

  • Piramal Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    3 Nov 2025, 5:30PM Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    3 Nov 2025, 5:25PM Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015\

  • Piramal Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    24 Oct 2025, 12:20PM Piramal Pharma Limited has informed the Exchange about Schedule of meet

  • Piramal Pharma - Board Meeting Intimation for Considering And Approving The Unaudited Financial Results (Standalone And Conso

    24 Oct 2025, 12:08PM Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2025 ,inter alia, to consider and a

  • Piramal Pharma has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2025

    17 Oct 2025, 3:40PM As of September 2025, 34.85% is owned by Indian Promoters, 64.63% by Public and 0.51% by Non Promoters-Non Public. <p align=justify> Institutional hol

  • Piramal Pharma - Credit Rating- Others

    16 Oct 2025, 8:45PM Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Withdrawal of Credit Rating.

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Credit Rating

    16 Oct 2025, 8:41PM Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Withdrawal of Credit Rating.

  • Piramal Pharma - Updates

    30 Sep 2025, 6:39PM Piramal Pharma Limited has informed the Exchange regarding 'intimation on change in the generic email id of Company's registrar & share transfer agent

  • Piramal Pharma - General - Update

    30 Sep 2025, 6:25PM Please find enclosed intimation on change in general email id of Company's Registrar & Share Transfer Agent.

  • Piramal Pharma - Updates

    9 Sep 2025, 6:56PM Piramal Pharma Limited has informed the Exchange regarding 'Amendment to the Code of Practices and Procedures for Fair Disclosure of Unpublished Price

  • Piramal Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    2 Sep 2025, 3:46PM Intimation of Schedule of Analyst/ Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    2 Sep 2025, 3:45PM Intimation of Schedule of Analyst/ Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

  • Piramal Pharma - Updates

    25 Aug 2025, 4:16PM Piramal Pharma Limited has informed the Exchange regarding 'Sustainability Report for the financial year 2024-25'.

  • Piramal Pharma - Sustainability Report - FY2024-25

    25 Aug 2025, 4:16PM Sustainability Report of Piramal Pharma Limited for the Financial Year 2024-25.

  • Piramal Pharma - Press Release

    21 Aug 2025, 5:00PM Press Release - Piramal Pharma Solutions (""PPS"") and NewAmsterdam Pharma invest indedicated suite to enhance Oral Solid Dosage capabilities at PPS'

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    21 Aug 2025, 4:56PM Press Release- Piramal Pharma Solutions ('\PPS\) and NewAmsterdam Pharma invest in dedicated suite to enhance Oral Solid Dosage capabilities at PPS' S

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Updates on Acquisition

    20 Aug 2025, 9:07PM Please refer attachment

  • Piramal Pharma - Acquisition

    20 Aug 2025, 8:56PM Piramal Pharma Limited has informed the Exchange about Completion of Acquisition

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    20 Aug 2025, 6:04PM Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015\

  • Piramal Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    20 Aug 2025, 6:02PM Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

  • Piramal Pharma

    21 Mar 2025 , 10:19AM Piramal Pharma arm gets market authorization for Neoatrico from United Kingdom’s Medicines and Healthcare Products Regulatory Agency. Neoatrico is a paediatric solution used in treatment for hypotension in neonates, infants, and children. Positive

  • Piramal Pharma

    19 Feb 2025 , 10:26AM Piramal Pharma: The US FDA issued Form 483 with six observations for the company’s Turbhe facility.

  • Piramal Pharma

    23 Jan 2025 , 9:39AM Piramal Critical Care launches Chlorpromazine Hydrochloride in US. With this launch, company continues to expand their generic injectables portfolio.

  • Piramal Pharma

    18 Apr 2024 , 11:50AM The US FDA had Inspected Piramal Pharma’s manufacturing facility located at Riverview, USA and has issued an Establishment Inspection Report (EIR) for the said manufacturing facility and the inspection has now been successfully closed by the US FDA. Positive

  • Piramal Pharma

    26 Feb 2024 , 12:37PM The US FDA conducted a Pre-Approval Inspection (PAI) inspection of Piramal Pharma Limited's Lexington (USA) facility from 20th February, 2024 to 23rd February, 2024 for one of the product expected to be manufactured at this facility. On conclusion of the inspection, a Form-483 was issued with 2 observations. The observations does not pose any risk to site’s compliance standards or its business continuity. The Company is preparing a detailed response to said observations, which will be submitted to the US FDA within stipulated timelines. (Positive).

  • Piramal Pharma

    17 Jan 2024 , 9:37AM Piramal Critical Care division has announced the launch of a new 10mg/10mL (1 mg/mL) concentration of Zinc Sulfate for Injection USP in the United States of America. The launch will enable PCC to further expand their zinc sulphate existing product line and overall generic injectable portfolio. Positive
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Piramal Pharma Ltd stock 

Name March-25 March-24 March-23 March-22
Assets 8674.47 7863.96 6889.07 6168.87
Liabilities 8674.47 7863.96 6889.07 6168.87
Equity 1324.35 1322.95 1193.32 1185.91
Gross Profit 1040.44 617.92 97.53 397.3
Net Profit 691.4 391.22 69.5 343.05
Cash From Operating Activities 548.77 358.29 71.52 255.2
NPM(%) 13.08 8.91 2.01 11.08
Revenue 5285.71 4390.11 3443.22 3094.95
Expenses 4245.27 3772.19 3345.69 2697.65
ROE(%) 8.73 4.94 0.87 4.33

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
16 Jul 2025 0.14 1.4 0 219.04
12 Jul 2024 0.11 1.1 0 150.45

Peers

Other companies within the same industry or sector that are comparable to Piramal Pharma Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 795.00 -2.44 0.00 109.61 301.39 0.63
Lotus Eye Hospital and Institute Ltd 103.05 -3.03 322.03 399.39 3.55 0.00
Vaishali Pharma Ltd 9.52 0.21 0.00 2505.52 3.13 0.00
Astec Lifesciences Ltd 649.35 1.91 0.00 376.64 -604.77 0.00

Company Info

Our Company was incorporated on March 4, 2020 at Mumbai as a public limited company under the Companies Act and was granted the certificate of incorporation by the RoC.Major events and milestones:2020-Acquired pharmaceutical business from PEL-20% Strategic Growth Investment by Carlyle-Increased stake to 100% in CCPL2021Acquisition of HPPL2022-Acquisition of minority stake in Yapan Bio Private Limited-Composite Scheme of Arrangement under the provisions of section 230 to 232 and other applicable provisions of the Companies Act, 2013 amongst PEL, the Company, CCPL, HPPL, PFPL and their respective shareholders and creditors, sanctioned by the NCLT on August 12, 2022. Pursuant to the Scheme, Demerged Undertaking of PEL, transferred and vested into the Company. 2020 -Piramal Pharma and Navin Fluorine Mutually Agree on Piramal Increasing its Stake to 100% in Convergence Chemicals. -Piramal Pharma Solutions to Collaborate with Epirium Bio on Exclusive Integrated Development & Manufacturing Program for Orphan Drugs. -Piramal Pharma Solutions Announces Integrated Development Program with Bolt Biotherapeutics for Immune-Stimulating Antibody Conjugates and Sterile Fill-Finish -Piramal Critical Care Announces Strategic Partnership with US-Based Pharmaceutical Outsourcing Facility Medivant Healthcare 2021 -Piramal Pharma Solutions Announces Winner of its Inaugural Award for Excellence in Patient Centricity. -Piramal Pharma Solutions Enters Into a Master Services Agreement with Plus Therapeutics, Inc. -Piramal Pharma Limited's Consumer Products Division Launches `i-feelr' 2022 -Piramal Pharma Solutions Announces Winner of its September 2022 Award for Excellence in Patient Centricity. -Piramal Pharma Solutions Launches ADCelerate, a Rapid, Integrated Approach to Taking ADCs to IND. -Piramal Pharma Solutions Holds Grand Opening Ceremony for New API Plant at Aurora, Canada Manufacturing Site. -Piramal Pharma Solutions New API Plant in Canada Goes Online; Initial Production Runs Successfully Completed. 2023 -Company issued rights shares of Rs. 10 in the ratio of 5:46 at a premium of Rs. 71 per share.

Our Company was incorporated on March 4, 2020 at Mumbai as a public limited company under the Companies Act and was granted the certificate of incorporation by the RoC.Major events and milestones:2020-Acquired pharmaceutical business from PEL-20% Strategic Growth Investment by Carlyle-Increased stake to 100% in CCPL2021Acquisition of HPPL2022-Acquisition of minority stake in Yapan Bio Private Limited-Composite Scheme of Arrangement under the provisions of section 230 to 232 and other applicable provisions of the Companies Act, 2013 amongst PEL, the Company, CCPL, HPPL, PFPL and their respective shareholders and creditors, sanctioned by the NCLT on August 12, 2022. Pursuant to the Scheme, Demerged Undertaking of PEL, transferred and vested into the Company. 2020 -Piramal Pharma and Navin Fluorine Mutually Agree on Piramal Increasing its Stake to 100% in Convergence Chemicals. -Piramal Pharma Solutions to Collaborate with Epirium Bio on Exclusive Integrated Development & Manufacturing Program for Orphan Drugs. -Piramal Pharma Solutions Announces Integrated Development Program with Bolt Biotherapeutics for Immune-Stimulating Antibody Conjugates and Sterile Fill-Finish -Piramal Critical Care Announces Strategic Partnership with US-Based Pharmaceutical Outsourcing Facility Medivant Healthcare 2021 -Piramal Pharma Solutions Announces Winner of its Inaugural Award for Excellence in Patient Centricity. -Piramal Pharma Solutions Enters Into a Master Services Agreement with Plus Therapeutics, Inc. -Piramal Pharma Limited's Consumer Products Division Launches `i-feelr' 2022 -Piramal Pharma Solutions Announces Winner of its September 2022 Award for Excellence in Patient Centricity. -Piramal Pharma Solutions Launches ADCelerate, a Rapid, Integrated Approach to Taking ADCs to IND. -Piramal Pharma Solutions Holds Grand Opening Ceremony for New API Plant at Aurora, Canada Manufacturing Site. -Piramal Pharma Solutions New API Plant in Canada Goes Online; Initial Production Runs Successfully Completed. 2023 -Company issued rights shares of Rs. 10 in the ratio of 5:46 at a premium of Rs. 71 per share.

Read More

Parent Organisation

Piramal Pharma Ltd.

Founded

04/03/2020

Managing Director

NSE Symbol

PPLPHARMAEQ

FAQ

The current price of Piramal Pharma Ltd is ₹ 192.13.

The 52-week high for Piramal Pharma Ltd is ₹ 195.88 and the 52-week low is ₹ 191.60.

The market capitalization of Piramal Pharma Ltd is currently ₹ 25538.84. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Piramal Pharma Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Piramal Pharma Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Piramal Pharma Ltd shares.

The CEO of Piramal Pharma Ltd is , who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT